The increasing prevalence of multi-drug-resistant bacteria represents one of the major threats to public health. β-Lactams remain the most widely used structural class of antibiotics; however, their effectiveness is decreasing due to excessive and often inappropriate use, which has led to the emergence of bacterial resistance mechanisms. Particularly problematic is resistance to β-lactams mediated by β-lactamases. While effective inhibitors are available against serine β-lactamases, the treatment of infections caused by bacteria expressing metallo-β-lactamases remains largely limited to the use of monobactams, which metallo-β-lactamases are unable to hydrolyse. The only clinically used representative of this class is aztreonam, whereas sulfazecin is the only known naturally occurring monocyclic β-lactam with antibacterial activity, produced by the bacterium Pseudomonas acidophila. Its biosynthetic precursor is desmethoxysulfazecin.
In this master’s thesis, desmethoxysulfazecin was synthesised via a multistep synthetic route. Emphasis was, however, on the development and optimisation of chromatographic methods enabling efficient isolation of desmethoxysulfazecin in sufficient purity for further studies. The requisite C3 side chain was prepared from commercially available Z-D-Glu-Obzl, which was first coupled with D-alanine tert-butyl ester. This was followed by removal of the tert-butyl protecting group and optimisation of chromatographic conditions for the isolation of diastereomerically pure carboxylic acid 2. In parallel, the monocyclic β-lactam building block 9 bearing a free amino group was prepared in seven steps starting from L-serine. After successful formation of the amide bond between fragments 2 and 9, removal of protecting groups by hydrogenation, and optimisation of chromatographic purification conditions, desmethoxysulfazecin (11) was successfully isolated.
Overall, optimisation of chromatographic conditions enabled more efficient separation of polar intermediates and isolation of the final product with satisfactory stereoisomeric purity. The chemical structure of desmethoxysulfazecin was confirmed by NMR and mass spectrometry, and the minimum inhibitory concentrations (MIC) of the final product against selected bacterial strains were also determined.
|